当前位置：
X-MOL 学术
›
Lancet Respir. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction to Lancet Respir Med 2024; 12: 799–809
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-18 , DOI: 10.1016/s2213-2600(24)00343-6
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2024-10-18 , DOI: 10.1016/s2213-2600(24)00343-6
Yu J, Jiang L, Zhao L, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med 2024; 12: 799-809—In this Article, figure 2A had some labelling errors with regard to the number at risk and numbered censored. These corrections have been made to the online version as of Oct 18, 2024.
更新日期：2024-10-19
京公网安备 11010802027423号